The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 8, 2010, Pages 1044-1050

  Misra, V L ^a   Vuppalanchi, R ^a   Jones, D ^a   Hamman, M ^a   Kwo, P Y ^a   Kahi, C ^a   Chalasani, N ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; FUROSEMIDE; MEGLUMINE IOTALAMATE; MIDODRINE; PLACEBO; SODIUM;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LIVER CIRRHOSIS; MALE; NATRIURESIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM URINE LEVEL; TREATMENT RESPONSE; UREMIA; URINE VOLUME;

ADMINISTRATION, ORAL; ASCITES; CREATININE; CROSS-OVER STUDIES; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; FUROSEMIDE; GLOMERULAR FILTRATION RATE; HUMANS; INFUSION PUMPS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIDODRINE; NATRIURESIS; SODIUM; URINATION; VASOCONSTRICTOR AGENTS;

EID: 77957237613     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04426.x     Document Type: Article

References (22)

1. Hoyert DL, Heron MP, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009 57: 1 135.
2. Sherlock S, Dooley J Ascites. In: Sherlock S, ed. Diseases of the Liver and Biliary System. 11th edn. London: Blackwell, 2002: 139.
3. Ruhl CE, Sayer B, Byrd-Holt DD, et al. Costs of digestive diseases. In: Everhart J, ed. The Burden of Digestive Diseases in the United States. Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. US Government Printing Office NIH Publication No. 09-6443, 2008: 137 146.
4. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Semin Liver Dis 1997 17: 163 173. (Pubitemid 27388055)
5. Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998 27: 264 272. (Pubitemid 28041563)
6. Arroyo V, Gines P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996 23: 164 176. (Pubitemid 26012105)
7. Brater DC. Diuretic therapy. N Engl J Med 1998 339: 387 395.
8. Villeneuve JP, Verbeeck RK, Wilkinson GR, et al. Furosemide kinetics and dynamics in patients with cirrhosis. Clin Pharmacol Ther 1986 40: 14 20.
9. Sawhney VK, Gregory PB, Swezey SE, et al. Furosemide disposition in cirrhotic patients. Gastroenterology 1981 81: 1012 1016.
10. Mirouze D, Zipser RD, Reynolds TB. Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983 3: 50 5. (Pubitemid 13175822)
11. Planas R, Arroyo V, Rimola A, et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983 84: 247 252. (Pubitemid 13224262)
12. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998 28: 937 943. (Pubitemid 28450253)
13. Voelker JR, Cartwright-Brown D, Anderson S, et al. Comparison of loop diuretics in patients with chronic renal insufficiency. Kidney Int 1987 32: 572 578. (Pubitemid 17154747)
14. Chalasani N, Gorski JC, Horlander JC Sr., et al. Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. J Am Soc Nephrol 2001 12: 1010 1016. (Pubitemid 32378342)
15. Al-Uzri A, Holliday MA, Gambertoglio JG, et al. An accurate practical method for estimating GFR in clinical studies using a constant subcutaneous infusion. Kidney Int 1992 41: 1701 1706.
16. Chennavasin P, Seiwell R, Brater DC. Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. J Pharmacol Exp Ther 1980 215: 77 81. (Pubitemid 11102256)
17. Chennavasin P, Seiwell R, Brater DC, et al. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979 16: 187 195. (Pubitemid 10223979)
18. Kaojarern S, Day B, Brater DC. The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int 1982 22: 69 74. (Pubitemid 12091220)
19. Agarwal R. Chromatographic estimation of iothalamate and p-aminohippuric acid to measure glomerular filtration rate and effective renal plasma flow in humans. J Chromatogr B Biomed Sci Appl 1998 705: 3 9. (Pubitemid 28045649)
20. Karwa R, Woodis CB. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother 2009 43: 692 699.
21. Kalambokis G, Fotopoulos A, Economou M, et al. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol 2007 46: 213 221. (Pubitemid 44959158)
22. Tandon P, Ross TT, Lesley M, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009 29: 169 174.